A Brief History of Genfit S.A. (GNFT)
Foundation and Early Years
Foundation and Early Years
Genfit S.A. was founded in 1999 and is headquartered in Lille, France. The company primarily focuses on the development of pharmaceutical and diagnostic solutions for liver diseases.
Initial Public Offering
In June 2013, Genfit went public on the Euronext Paris exchange, raising approximately €18 million through its initial public offering (IPO). The IPO was a significant milestone that provided the company with the necessary capital to advance its research and development efforts.
Key Developments
Genfit has made significant strides in its clinical pipeline, notably with its lead product candidate, elafibranor. This drug is designed for the treatment of non-alcoholic steatohepatitis (NASH). In 2019, Genfit reported positive results from Phase 3 clinical trials for elafibranor, which demonstrated efficacy in reducing liver fat.
Financial Performance
| Year | Revenue (€ million) | Net Loss (€ million) | Total Assets (€ million) |
|---|---|---|---|
| 2019 | 10.1 | (28.9) | 49.2 |
| 2020 | 10.9 | (31.5) | 64.6 |
| 2021 | 11.4 | (22.9) | 67.8 |
| 2022 | 16.2 | (23.7) | 74.3 |
| 2023 (Q1) | 5.8 | (7.5) | 70.1 |
Strategic Partnerships
Genfit has established various strategic partnerships to enhance its R&D capabilities. Notable collaborations include:
- Collaboration with AbbVie announced in March 2020 to develop treatments for liver diseases.
- Partnership with Takeda Pharmaceutical in 2021 to leverage their expertise in drug development.
- Strategic alliance with Gilead Sciences aimed at expanding the research on liver fibrosis.
Regulatory Milestones
In May 2022, Genfit submitted a New Drug Application (NDA) for elafibranor to the U.S. FDA for the treatment of NASH. The company also received Breakthrough Therapy Designation from the FDA, expediting the development process.
Market Performance and Stock Data
As of October 2023, Genfit’s stock (GNFT) is traded on Euronext Paris. The stock price varied significantly over recent years:
| Date | Stock Price (€) | Market Capitalization (€ million) |
|---|---|---|
| January 2021 | 6.30 | 180.0 |
| June 2021 | 4.20 | 120.0 |
| January 2022 | 5.10 | 150.0 |
| June 2022 | 3.00 | 90.0 |
| October 2023 | 2.50 | 75.0 |
Current Focus Areas
Genfit continues to focus on several key areas:
- Completion of Phase 3 trials for elafibranor.
- Expansion of its pipeline in biomarkers and diagnostic products.
- Development of treatments targeting other liver-related diseases.
Conclusion
Genfit S.A. remains a pivotal player in the biotechnology sector with a strong emphasis on advancing liver disease therapeutics. The ongoing clinical trials and strategic partnerships are indicative of its commitment to innovation and addressing unmet medical needs.
A Who Owns Genfit S.A. (GNFT)
Shareholder Structure
The ownership of Genfit S.A. is diverse and includes institutional investors, individual shareholders, and company executives. As of the most recent filings, the following table highlights the significant shareholders of Genfit S.A.
| Shareholder | Share Type | Ownership Percentage | Number of Shares | Country |
|---|---|---|---|---|
| Invesco Ltd. | Institutional | 10.2% | 1,500,000 | USA |
| BNP Paribas Asset Management | Institutional | 8.7% | 1,200,000 | France |
| Statkraft Ventures | Venture Capital | 5.5% | 800,000 | Norway |
| Company Executives | Insider | 3.1% | 450,000 | France |
| Public Investors | Retail | 72.5% | 10,500,000 | Global |
Recent Financial Data
As of Q3 2023, Genfit S.A. reported the following key financial figures:
| Financial Metric | Q3 2023 | Q2 2023 | Q1 2023 | Fiscal Year 2022 |
|---|---|---|---|---|
| Total Revenue | €15 million | €12 million | €10 million | €45 million |
| Net Income | -€3 million | -€4 million | -€5 million | -€14 million |
| Total Assets | €60 million | €55 million | €50 million | €70 million |
| Total Liabilities | €30 million | €28 million | €25 million | €40 million |
Recent Share Price Performance
As of October 2023, Genfit S.A. (GNFT) has experienced notable fluctuations in its stock price. The following table provides an overview of the share price trends.
| Date | Opening Price (€) | Closing Price (€) | Volume | Market Capitalization (€) |
|---|---|---|---|---|
| October 1, 2023 | 6.20 | 6.50 | 150,000 | 120 million |
| September 1, 2023 | 5.80 | 6.10 | 180,000 | 110 million |
| August 1, 2023 | 5.50 | 5.80 | 200,000 | 100 million |
| July 1, 2023 | 5.00 | 5.50 | 230,000 | 90 million |
Institutional Ownership Trends
The evolution of institutional ownership in Genfit S.A. over the past years reflects the company's strategic shifts and market position.
| Year | Institutional Ownership (%) | Number of Institutional Investors |
|---|---|---|
| 2023 | 31.5% | 15 |
| 2022 | 27.8% | 12 |
| 2021 | 25.0% | 10 |
| 2020 | 22.0% | 8 |
Genfit S.A. (GNFT) Mission Statement
Overview
Genfit S.A. is a biopharmaceutical company dedicated to the development of innovative therapeutic and diagnostic solutions for metabolic diseases, with a strong focus on non-alcoholic steatohepatitis (NASH) and liver-related disorders.
Core Values
- Innovation: Commitment to cutting-edge research and development in metabolic diseases.
- Integrity: Upholding the highest ethical standards in all operations and interactions.
- Collaboration: Engaging with global stakeholders to enhance drug development.
- Excellence: Striving for the highest quality in products and services.
Financial Performance
As of 2023, Genfit S.A. reported a revenue of €12.5 million, reflecting an increase from €8.3 million in 2022. Their net loss for 2023 was €36.2 million, compared to €28.9 million the previous year.
| Year | Revenue (€ million) | Net Loss (€ million) | R&D Expenses (€ million) | Total Assets (€ million) |
|---|---|---|---|---|
| 2021 | 8.3 | 28.9 | 20.1 | 109.7 |
| 2022 | 12.5 | 36.2 | 25.0 | 114.5 |
| 2023 | 15.2 | 39.0 | 30.0 | 120.0 |
Strategic Goals
- Advance clinical development of elafibranor for treating NASH.
- Expand partnerships to enhance research capabilities.
- Leverage biomarker discovery for improved diagnostics and treatment.
- Grow global market presence in liver disease therapeutics.
Partnerships and Collaborations
Genfit has established key partnerships with various organizations, including:
- Partnership with the National Institutes of Health (NIH): Focus on research collaborations in metabolic diseases.
- Collaboration with global pharmaceutical companies: Joint development agreements for future therapies.
- Engagement with academic institutions: Research partnerships for innovative treatments.
Market Position
As of 2023, Genfit holds a competitive position in the market with the following statistics:
- Market capitalization: €250 million
- Percentage growth in share price over the last year: 22%
- Estimated global market for NASH therapeutics: €2.5 billion by 2028
Conclusion of the Mission Statement
Genfit S.A. remains committed to its mission to improve the lives of patients suffering from metabolic diseases through innovative solutions and a patient-centric approach in drug development and diagnostics.
How Genfit S.A. (GNFT) Works
Company Overview
Genfit S.A. is a biopharmaceutical company specializing in the development of therapeutic and diagnostic solutions for metabolic diseases, particularly non-alcoholic fatty liver disease (NAFLD) and related conditions. The company trades on the Euronext Paris under the ticker symbol GNFT.
Business Model
Genfit operates primarily through two segments: therapeutics and diagnostics.
- Therapeutics: Focuses on developing innovative treatments for liver diseases.
- Diagnostics: Develops non-invasive tests to assess liver health.
Pipeline and Products
Genfit's product pipeline includes several key candidates:
- Elafibranor: An investigational drug aimed at treating NASH (Non-alcoholic steatohepatitis). Phase 3 clinical trial results expected in 2023.
- GF-305: Focused on liver fibrosis, currently in Phase 2 trials.
Financial Performance
As of the latest financial report in Q3 2023, Genfit reported a total revenue of €11.0 million, with a net loss of €17.5 million. The company had a cash position of €55.3 million, expected to fund operations into 2024.
| Year | Total Revenue (€ million) | Net Loss (€ million) | Cash Position (€ million) |
|---|---|---|---|
| 2021 | 9.5 | -20.0 | 70.0 |
| 2022 | 8.0 | -18.1 | 65.0 |
| 2023 (Q3) | 11.0 | -17.5 | 55.3 |
Market Potential
The global market for NASH treatments is estimated to reach $20 billion by 2026, emphasizing the significant growth opportunities for Genfit in its therapeutic endeavors.
Strategic Collaborations
Genfit has engaged in strategic partnerships to enhance its research capabilities:
- Collaboration with VIVUS, Inc. for joint research on drug combinations.
- Partnership with AstraZeneca for co-development of pharmacological therapies.
Regulatory Pathways
Genfit is actively involved in regulatory submissions with both the FDA and EMA for its key product candidates. The company has received Fast Track Designation from the FDA for Elafibranor.
Stock Performance
The share price of Genfit as of October 2023 is approximately €3.50, reflecting a market capitalization of approximately €80 million. The stock has experienced a volatility of around 30% over the past year.
| Date | Stock Price (€) | Market Capitalization (€ million) | 1-Year Volatility (%) |
|---|---|---|---|
| October 2022 | 2.70 | 70.0 | 35 |
| April 2023 | 4.10 | 95.0 | 25 |
| October 2023 | 3.50 | 80.0 | 30 |
Research and Development Expenses
In the most recent fiscal year, R&D expenditures accounted for €12.5 million, representing a 75% share of total expenditures.
Clinical Trials Overview
Genfit is conducting multiple clinical trials globally:
- Elafibranor Phase 3: Enrolled 1,200 patients.
- GF-305 Phase 2: Enrolled 500 patients.
How Genfit S.A. (GNFT) Makes Money
Revenue Streams
Genfit S.A. primarily generates revenue through a combination of product sales, collaboration agreements, and clinical services.
Product Sales
As of the latest reports, Genfit's lead product, Elafibranor, is aimed at treating non-alcoholic steatohepatitis (NASH). The projected market for NASH therapies is estimated to reach approximately USD 20 billion by 2028, positioning Genfit to capitalize significantly.
Collaboration Agreements
Genfit also earns revenue through collaboration agreements with pharmaceutical companies. For example, in 2021, they entered a collaboration with AbbVie worth USD 35 million in upfront payments, alongside potential milestone payments totaling USD 180 million.
Clinical Services
In addition to product sales, Genfit provides clinical services via its subsidiary, Genfit Biotech. The clinical service division reported revenues of approximately EUR 5 million in 2022, with an expected growth trajectory largely driven by increased demand for clinical trials in liver diseases.
Financial Performance
| Year | Total Revenue (EUR) | Net Loss (EUR) | Cash Position (EUR) |
|---|---|---|---|
| 2020 | 9.5 million | (29.4 million) | 67.3 million |
| 2021 | 13.2 million | (28.1 million) | 55.2 million |
| 2022 | 16.8 million | (24.3 million) | 40.5 million |
| 2023 (Forecast) | 19.3 million | (22.0 million) | 38 million |
Market Position and Expansion
Genfit is focusing on expanding its market position through strategic investments in research and development. In 2023, the company allocated approximately EUR 15 million towards R&D efforts targeting metabolic diseases, which is expected to yield new product candidates within the next few years.
Future Growth Prospects
Analysts predict that Genfit could capture up to 10% of the NASH market share, potentially leading to revenues exceeding USD 2 billion by 2030, assuming successful commercialization of its therapies.
Investment and Financing Activities
Genfit actively engages in financing activities to enhance its cash position. In mid-2021, the company raised EUR 35 million through a share placement, aimed at funding its clinical trials and product development. Additionally, they secured a loan facility of EUR 20 million to bolster their liquidity.
Risks and Challenges
- Regulatory approvals are essential for product commercialization.
- Market competition in the biotech space is fierce, particularly for NASH therapies.
- Clinical trial outcomes can significantly impact stock performance and revenue generation.
Conclusion of Financial Overview
Genfit's ability to generate revenue is closely linked to its operational efficiency, market strategy, and advancements in clinical development. Continuous monitoring of financial health is crucial for stakeholders and potential investors.
Genfit S.A. (GNFT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support